
Currently: 1st year Hem/Onc fellow @MDAndersonNews Previously: IM residency @YaleIMed | Research fellow @BIDMChealth MD & PhD @uoaofficial
Houston, Texas
Joined July 2021
- Tweets618
- Following667
- Followers1.1K
- Likes2.7K
Pinned Tweet
Excited to share our work about the role of PD-1/SHP-2 signaling in myeloid cell differentiation and anti-tumor immunity. We started this project approximately 4 years ago at Dr. Boussiotis’ lab and today it is finally published in Nature Immunology.
nature.com/articles/s41590-0…
Anthos Christofides retweeted
My lab is hiring talented and motivated individuals at all levels of training. Our mission is to understand how epigenetic dysregulation drives sarcoma development and plasticity and to translate these insights into new therapies. Please apply at the following links.
Anthos Christofides retweeted
Grateful to share my 1st trial publication in the MM field and with the @UTMDAnderson MM group (hopefully the first of many, following the path @Myeloma_Doc is kindly helping me pave). Huge thanks to Dr. Pasvolsky and @Transplant_Doc for trusting me with this opportunity. Above all, thanks to patients, families, and study coordinators who made it possible.
#Myeloma Paper of the Day: Single-center phase 2 of daratumumab ± pomalidomide as maintenance post-ASCT finds ≥CR rate increased to 85%, MRD- (<10–5) in 75%; median PFS 45.1 months among pts w/ 2–4 prior treatments; 10 yr RMST from dx of 9.8 years: pubmed.ncbi.nlm.nih.gov/4280…. #mmsm
Anthos Christofides retweeted
Sharing our recent manuscript highlighting DLL3 IHC predictive of tarlatamab response and long-term outcome, check this out!
Key findings:
1. DLL3 IHC expression in patient tissue ranging widely from 0% to 100% (median of 70% and 75%, in two datasets)
2. DLL3 expression above 75% experienced a significantly longer median time on tarlatamab (ToT)treatment (10.1 months vs. 2.9 months) compared to those with ≤75% expression.
3. Patients achieving a PR to tarlatamab had a higher median DLL3 expression level (80%) than those with PD (40%)
biorxiv.org/content/10.64898… @LaurenByersMD @LauraAlderMD @lungoncdoc @drshieldsmd @kyleconcannonMD @SclcSMASHERS k
Anthos Christofides retweeted
➡️ Check out our poster evaluating the dynamics of MDS related muts in ND AML treated with LIT+Venetoclax 🧬 @SocietyofHemOnc #AML Poster520.
Great work @naszrinMD on this analysis.
@garciamanero @Daver_Leukemia @UTMDAnderson – at West University Place, TX
Grateful to @jayastuMD for his mentorship on our work being presented at #SOHO2026! We found that myelodysplasia-related mutation clearance in newly diagnosed AML treated with low-intensity therapy was associated with improved survival. #AML @UTMDAnderson @SocietyofHemOnc
Anthos Christofides retweeted
Λέμε στα πανεπιστήμια:
Οι άριστοι επιλέγουν καλύτερους από τους ίδιους.
Οι καλοί επιλέγουν μέτριους.
Οι μέτριοι επιλέγουν χειρότερους.
Ο κανόνας αυτός επιβεβαιώνεται σήμερα και στην πολιτική, σε όλα τα επίπεδα εξουσίας.
Πίσω στη δεκαετία του ’60.
Τα μαύρα Δευτέρια είναι κατάμαυρα
Anthos Christofides retweeted
Today is my first day as Assistant Professor back at my alma mater @UWMadison @uwsmph @UWHealth @UWCarbone.
Anthos Christofides retweeted
Thrilled to be part of the incredible @pewtrusts community !
Congrats to professor Christina Tringides, recipient of the prestigious @Pewtrusts Biomedical Scholar award. This award supports her development of next-generation cancer models to advance #glioblastoma research. news.rice.edu/news/2026/rice…
Honored to present correlative analyses from the C3NIRA study in patients with Aggressive Variant Prostate Cancer at #ASCO26. Grateful to Dr. @aaparicioMD and the entire team for their mentorship and support.
Anthos Christofides retweeted
The third ASCO poster session featured research spanning prostate, kidney, skin, and lung cancers, with studies exploring new biomarkers, treatment strategies, clinical trials, and approaches to improving patient outcomes.
A few highlights from UT MD Anderson investigators are in the thread below. #EndCancer 1/7
Anthos Christofides retweeted
New insights from the C3NIRA study suggest early changes in the tumor microenvironment after chemotherapy may help identify patients with aggressive variant prostate cancer who are most likely to benefit from PD-1 blockade.
Presented by Anthos Christofides at #ASCO26, the findings could help refine patient selection for immunotherapy and guide future treatment strategies. @AntChristofides @aaparicioMD #EndCancer 2/7
Anthos Christofides retweeted
Blessed and humbled to receive the Outstanding Publication Award by @HRSonline in #HRS26! I want to cordially thank my mentors at @UMN_DCVM and @hopkinsheart for their trust and guidance!
Congratulations to Marinos Kosmopoulos, MD, this year’s winner of the Heart Rhythm Journal Outstanding Publication Award in Clinical Research! #HRS2026
Read the article: bit.ly/4eifJHJ @kosmopolitanmd @hrs_journal
Anthos Christofides retweeted
Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72)
- ORR: 76%
- Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response
- New SoC
#lcsm #LungCancer #OncTwitter
Anthos Christofides retweeted
📖 New online from our group at @MDAndersonNews Mechanisms of Resistance to Trastuzumab-DXd in #LungCancer 🔬✨ Key findings:
👉 Payload resistance driven by #SLFN11 loss and copy-number gains in the efflux pump ABCC1/MRP1
👉 Secondary #HER2 extracellular domain mutations at the antibody binding site (e.g., D582, F595)
👉 Tumors with acquired payload resistance or domain IV mutations retain HER2 signaling and remain sensitive to TKIs, including #zongertinib and #sevabertinib
💡 🎊 🔥 This is the first comprehensive preclinical and clinical investigation of #ADC #MoR in lung cancer, with direct therapeutic implications.
jto.org/article/S1556-0864%2…
Anthos Christofides retweeted
Excited to be staying at Yale to continue my training in Cardiology! Grateful for the support and mentorship. Looking forward to the next chapter! @YaleIMed @YaleCardiology
Anthos Christofides retweeted
☀️The menin inhibitors space in acute leukemias is getting exciting: ➡️ we report the phase 1 first-in-human clinical and PK results of DS-1594 menin inhibitor led by @Daver_Leukemia.
rdcu.be/eR8wp
Due to portfolio realignment the study was stopped at ph 1 before an efficacious dose level was achieved but activity was noted along with DS. – at Texas Medical Center, Houston
Anthos Christofides retweeted
Χασαπόπουλε, το Ερευνητικό Κέντρο “Φαέθων” δεν έχει καμία απολύτως σχέση με το φωτοβολταϊκό πάρκο “Φαέθων”. Πρόκειται για δύο εντελώς διαφορετικές οντότητες.
Συνέχισε έτσι. Σήμερα έδωσες στους δικηγόρους μου ακόμη περισσότερα στοιχεία. Ευχαριστώ. Έρχεται…
This quoted post is unavailable.
Anthos Christofides retweeted
Εγώ δεν είμαι ούτε του Άλματος, ούτε του Φειδία. Ήμουν, ως στέλεχος των ΤΥ του ΠΚ, συντονιστής του Φαέθων - το οποίο μάλιστα βραβεύτηκε με 1ο βραβείο για Πράσινες Δημόσιες Συμβάσεις! Φτάνει ψέματα κ. Χασαπόπουλε!
Anthos Christofides retweeted
Αυθεντικός Μαραθώνιος Αθήνας. 42,195 χιλιόμετρα γεμάτα πόνο, μέχρι τη στιγμή που περνάς στο Καλλιμάρμαρο και ο πόνος γίνεται καθαρή συγκίνηση και υπερηφάνεια. 🇬🇷
Anthos Christofides retweeted
Τα παραμύθια στις περιοδείες σας στην ύπαιθρο. Ήρθατε στα εγκαίνια του CCRI (Κυπριακού Ινστιτούτου Έρευνας Καρκίνου) - υποσχεθήκατε στήριξη.
3 χρόνια μετά, αρνείστε να το χρηματοδοτήσετε.
Το CCRI κινδυνεύει να κλείσει.
Γιατί μισείτε τόσο πολύ τους νέους ερευνητές &την επιστήμη;
Anthos Christofides retweeted
Αγαπητέ Χρύσανθε είναι ευρέως γνωστό ότι ο κ. @a_hassapopoulos συχνά αναφέρει ανακρίβειες & λανθασμένα στοιχεία . Εσείς όμως, ως φιλοξενών δημοσιογράφος, οφείλατε να του κάνετε την πιο απλή & καθοριστική ερώτηση:
Σε ποιο ποσό κατακυρώθηκε το έργο μετά από τον διεθνή διαγωνισμό;
Τι ακριβώς έγινε με τη βιβλιοθήκη Στέλιου Ιωάννου κ Χασαπόπουλε;
instagram.com/reel/DQGsVSGCJ…
















































